Another therapeutic option has now become available for treatment of amyotrophic lateral sclerosis (ALS). Edaravone is manufactured by Japanese Mitsubishi Tanabe Pharma Corp’s.
Edaravone is the first product for treatment of ALS developed within the last 22 years. Until recently, patients suffering from that disease were only treated with Rilusol – until now, the sole product significantly delaying the disease progression.
Clinical trials (randomized, placebo-controlled) have shown, that Edaravone for intravenous administration helps delay the process of depression of vital functions in patients by one third. Such an effect was observed after six months of treatment with Edaravone, as it was administered intravenously for 14 days with further 14-day break. It was followed by 10 daily injections with a 14-day break.
Food and Drug Administration (FDA) approved that product. In USA it will be marketed under the trade-mark Radicava. It has been assigned an orphan status.